Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients

Bibliography

• AGIS Investigators. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Miglior S, Zeyen T, Pfeiffer N, Results of the European glaucoma prevention study. Ophthalmology 2005;112(3):366-75
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society Guidelines. Terminology and guidelines for glaucoma. 3rd edition. Editrice DOGMA; Savona, Italy; 2008. p. 117-53
   Google Scholar
• Nakajima T, Matsugi T, Goto W, New fluoroprostaglandin F2a derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 2003;26:1691-5
   PubMed Web of Science ®Google Scholar
• Ota T, Murata H, Sugimoto E, Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci 2005;46:2006-11
   PubMed Web of Science ®Google Scholar
• Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 2007;23:359-65
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol 2008;86:S242; 14-19
   Web of Science ®Google Scholar
• Traverso CE, Ropo A, Papadia M, A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther 2010;26:97-104
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open angle glaucoma and ocular hypertension: 24-months results of a randomized, double masked phase III study. Acta Ophthalmol 2010;88:12-19
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol 2008;86:S242; 7–13
   Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eye drops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26
   PubMed Web of Science ®Google Scholar
• Rossi GC, Tinelli C, Pasinetti GM, Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009;4:572-9
   Google Scholar
• Baudouin C, Labbe A, Liang H, Preservatives in eye drops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Tseng SC, Sanabria O, Evaluation of subjective assessment and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-9
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Pasinetti GM, Scudeller L, The Italian version of the Glaucoma Symptoms Scale: translation, validation and reliability. J Glaucoma 2012;21(9); in press
   Google Scholar
• Jampel HD, Schwartz GF, Robin AL, Patient preferences for eye drop characteristics. A willingness to pay analysis. Arch Ophthalmol 2003;121:540-6
   PubMed Web of Science ®Google Scholar
• Hommer A, Ramez OM, Burchert M, IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.. Curr Med Res Opin 2010;26:1905-13
   PubMed Web of Science ®Google Scholar
• Erb C, Lanzl I, Seidova SF, Preservative-Free Tafluprost 0.0015% in the Treatment of Patients with Glaucoma and Ocular Hypertension. Adv Ther 2011;28:575-85
   PubMed Web of Science ®Google Scholar
• AGIS investigators: The Advanced Glaucoma Intervention Study (AGIS):14. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophtalmol 2002;134:499-512
   PubMed Web of Science ®Google Scholar
• Baudouin C, de Lunardo C. Short term comparative study of topical 2% cartelol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42
   PubMed Web of Science ®Google Scholar
• Xiong C, Chen D, Liu J, A rabbit model induced by topical medication of a preservative Benzalkonium Chloride. Invest Ophthalmol Vis Sci 2008;49:1850-6
   PubMed Web of Science ®Google Scholar
• Guenoun JM, Badouin C, Rat P, In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci 2005;46:2444-50
   PubMed Web of Science ®Google Scholar